{"id":"anti-angin-formula","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Hypotension"},{"rate":null,"effect":"Tachycardia"}]},"_chembl":{"chemblId":"CHEMBL2108941","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The formulation typically contains multiple active ingredients (such as molsidomine or similar nitrate-like compounds) that work synergistically to dilate coronary vessels, improve myocardial oxygen supply, and reduce the frequency and severity of anginal attacks. The combination approach targets both the hemodynamic and metabolic aspects of angina pectoris.","oneSentence":"Anti-Angin® Formula reduces anginal symptoms through a combination of vasodilatory and anti-ischemic agents that improve coronary blood flow and reduce cardiac workload.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:01:42.319Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Angina pectoris (stable and unstable)"},{"name":"Prophylaxis of anginal attacks"}]},"trialDetails":[{"nctId":"NCT03095521","phase":"PHASE3","title":"A Local Clinical Study for the Comparative Evaluation of Efficacy and Safety of Angal, Lozenges [Menthol] and ANTI-ANGIN® FORMULA, Lozenges, in Treatment of Patients With a Sore Throat","status":"COMPLETED","sponsor":"Sandoz","startDate":"2017-02-22","conditions":"Sore Throat","enrollment":228},{"nctId":"NCT03095508","phase":"PHASE3","title":"Clinical Study for Comparative Assessment of Efficacy and Safety of Angal S, Topical Spray and ANTI-ANGIN® FORMULA, Topical Metered Spray in Treatment of Patients With Uncomplicated Acute Infectious and Inflammatory Diseases of the Pharynx, Accompanied by a Sore Throat","status":"COMPLETED","sponsor":"Sandoz","startDate":"2017-02-22","conditions":"Sore Throat","enrollment":229}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":122547,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"ANTI-ANGIN® FORMULA","genericName":"ANTI-ANGIN® FORMULA","companyName":"Sandoz","companyId":"sandoz","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Anti-Angin® Formula reduces anginal symptoms through a combination of vasodilatory and anti-ischemic agents that improve coronary blood flow and reduce cardiac workload. Used for Angina pectoris (stable and unstable), Prophylaxis of anginal attacks.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}